Alemtuzumab in refractory Sézary syndrome

Anais Brasileiros de Dermatologia

关键词: Antibodies, monoclonal, humanized;    Lymphoma, T-Cell, cutaneous;    Sézary syndrome;    Treatment outcome;   

DOI  :  10.1590/abd1806-4841.20164322

来源: DOAJ

【 摘 要 】

Abstract: Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by the triad of erythroderma, lymphadenopathy and circulating atypical cells. The emergence of new molecular targets has enabled the development of drugs such as alemtuzumab, an anti-CD52 monoclonal antibody, which has shown promising results in the treatment of this entity. We report the case of a 70-year-old male with refractory Sézary syndrome in whom treatment with alemtuzumab achieved an 80% skin lesion clearance with complete haematologic and radiologic response. The treatment was discontinued after 4 months due to adverse effects, with the patient showing a sustained response without disease progression after 13 months of follow-up.

【 授权许可】

Unknown